Novo Nordisk's GLP-1 agonist Wegovy received accelerated FDA approval for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), expanding its label to a patient population estimated at 22 million in the US alone. This marks the first GLP-1 treatment approved for MASH, a condition with limited therapeutic options. The approval is underpinned by Phase 3 data showing improvements in liver scarring and MASH resolution. The development intensifies competition with Madrigal Pharmaceuticals' thyroid hormone agonist Rezdiffra, which has shown strong sales. Market analysts foresee segmentation where Wegovy is preferred for metabolic-associated cases, while other MASH patients may opt for alternative therapies. The deal underscores the expanding role of GLP-1 drugs beyond weight loss and diabetes treatment.